# Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

> **NCT01521143** · PHASE2 · TERMINATED · sponsor: **Prima BioMed Ltd** · enrollment: 91 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **BIOLOGICAL:** Cvac
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01521143
- **Lead sponsor:** Prima BioMed Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** The study was terminated due to company restructuring and changes in drug development priorities.
- **Last updated:** 2016-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01521143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01521143, "Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01521143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*